BCPS Exam 2024/2025 Questions and Answers (Graded
A)
____ is the most appropriate answer because there are no drug-drug interactions or
contraindications / cautions in HIV - ANSWER Bictegravir
n patients with persistent neutropenic fever despite anti-pseudomonal coverage,
what should be considered? - ANSWER empiric antifungal therapy should be
considered after 4 - 10 days
electrocautery - ANSWER Which of the following therapies is most likely to result in
a resolution rate which approaches 100% in patients w/ external anogenital warts.?
preferred therapy for CMV retinitis? - ANSWER Ganciclovir intravitreal injections plus
valganciclovir oral
bacterial vaginosis recommended treatment - ANSWER clindamycin or
metronidazole
(i.e. Clindamycin 300 mg orally twice daily for 7 days)
recommended treatment regimen for pelvic inflammatory disease - ANSWER
Ceftriaxone 250 mg intramuscularly x 1 dose plus doxycycline 100 mg orally twice
daily for 14 days
vulvovaginal candidiasis teeatment - ANSWER Clindamycin cream 2%, 5 g
intravaginally at bedtime for 7 days
MedWatch - ANSWER preferred route for healthcare professionals and patients to
report suspected adverse events to the FDA
FDA Form 3500A - ANSWER mechanism for reporting suspected adverse events,
but is reserved for use by user-facilities, importers, distributors, and manufacturers
-reporting errors related to vaccines - ANSWER ISMP VERP and VAERS
viral rhinosinusitis sx duration - ANSWER -peak at 3 days and may persist longer
than 14 days but usually decreases in severity by 10 days
-watchful waiting is recommended to avoid overuse of antibiotics as episodes are
often self-limited
Malignant external otitis treatment - ANSWER - predominantly caused by
Pseudomonas aeruginosa
-antipseudomonal antimicrobials are considered the mainstay of therapy.
, Fidaxomicin - ANSWER -associated with decreased recurrence of Clostridioides
difficile likely owing to its narrow spectrum and minimal effect on normal colonic flora
duration of initial therapy for CDI? - ANSWER 10 days with oral vancomycin or
fidaxomicin
MRSA PCR - ANSWER -well-recognized tool for antimicrobial de-escalation as part
of stewardship initiatives given the high negative predictive value
MRSA nasal culture - ANSWER -used for surveillance and is not employed as a
stewardship tool
Procalcitonin - ANSWER -useful in differentiating between viral and bacterial
etiologies
-chronic kidney disease may cause an artificially high level leading to questionable
interpretation and potential continuation of inappropriate antimicrobials
Asymptomatic candiduria - ANSWER -common among hospitalized patients with an
indwelling urinary catheter and treatment is nt is not warranted
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) -
ANSWER Elvitegravir is only available in single-tablet regimen form; either as
EVG/c/FTC/TAF or EVG/c/FTC/TDF. Therefore, it is not possible to stock the single
agents and "break up" the patient's regimen
Waterfall plot - ANSWER -Waterfall plot is ideal to represent secondary objectives.
BRAF Mutation - ANSWER BRAF mutation confers resistance to EGFR inhibitors;
Anti-EGFR therapies should be avoided in KRAS WT and BRAF mutant mCRC
unless given in combination with BRAF inhibitor
Palbociclib - ANSWER -FDA approval for male breast cancer in combination with an
aromatase inhibitor or fulvestrant for men with hormone receptor-positive (HR+),
human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic
breast cancer
Atezolizumab combined with nab-paclitaxel - ANSWER -in breast CA is based on the
PD-L1 expression on tumor-infiltrating immune cells
Olaparib - ANSWER -Breast cancer
-metastatic,
-HER2-negative -germline BRCA-mutated (gBRCAm)
Tvec indication - ANSWER -second-line setting
- patients with skin involvement
-not metastatic
platinum-sensitive disease - ANSWER =/> 6 months
<6 months - ANSWER platinum refractory
A)
____ is the most appropriate answer because there are no drug-drug interactions or
contraindications / cautions in HIV - ANSWER Bictegravir
n patients with persistent neutropenic fever despite anti-pseudomonal coverage,
what should be considered? - ANSWER empiric antifungal therapy should be
considered after 4 - 10 days
electrocautery - ANSWER Which of the following therapies is most likely to result in
a resolution rate which approaches 100% in patients w/ external anogenital warts.?
preferred therapy for CMV retinitis? - ANSWER Ganciclovir intravitreal injections plus
valganciclovir oral
bacterial vaginosis recommended treatment - ANSWER clindamycin or
metronidazole
(i.e. Clindamycin 300 mg orally twice daily for 7 days)
recommended treatment regimen for pelvic inflammatory disease - ANSWER
Ceftriaxone 250 mg intramuscularly x 1 dose plus doxycycline 100 mg orally twice
daily for 14 days
vulvovaginal candidiasis teeatment - ANSWER Clindamycin cream 2%, 5 g
intravaginally at bedtime for 7 days
MedWatch - ANSWER preferred route for healthcare professionals and patients to
report suspected adverse events to the FDA
FDA Form 3500A - ANSWER mechanism for reporting suspected adverse events,
but is reserved for use by user-facilities, importers, distributors, and manufacturers
-reporting errors related to vaccines - ANSWER ISMP VERP and VAERS
viral rhinosinusitis sx duration - ANSWER -peak at 3 days and may persist longer
than 14 days but usually decreases in severity by 10 days
-watchful waiting is recommended to avoid overuse of antibiotics as episodes are
often self-limited
Malignant external otitis treatment - ANSWER - predominantly caused by
Pseudomonas aeruginosa
-antipseudomonal antimicrobials are considered the mainstay of therapy.
, Fidaxomicin - ANSWER -associated with decreased recurrence of Clostridioides
difficile likely owing to its narrow spectrum and minimal effect on normal colonic flora
duration of initial therapy for CDI? - ANSWER 10 days with oral vancomycin or
fidaxomicin
MRSA PCR - ANSWER -well-recognized tool for antimicrobial de-escalation as part
of stewardship initiatives given the high negative predictive value
MRSA nasal culture - ANSWER -used for surveillance and is not employed as a
stewardship tool
Procalcitonin - ANSWER -useful in differentiating between viral and bacterial
etiologies
-chronic kidney disease may cause an artificially high level leading to questionable
interpretation and potential continuation of inappropriate antimicrobials
Asymptomatic candiduria - ANSWER -common among hospitalized patients with an
indwelling urinary catheter and treatment is nt is not warranted
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) -
ANSWER Elvitegravir is only available in single-tablet regimen form; either as
EVG/c/FTC/TAF or EVG/c/FTC/TDF. Therefore, it is not possible to stock the single
agents and "break up" the patient's regimen
Waterfall plot - ANSWER -Waterfall plot is ideal to represent secondary objectives.
BRAF Mutation - ANSWER BRAF mutation confers resistance to EGFR inhibitors;
Anti-EGFR therapies should be avoided in KRAS WT and BRAF mutant mCRC
unless given in combination with BRAF inhibitor
Palbociclib - ANSWER -FDA approval for male breast cancer in combination with an
aromatase inhibitor or fulvestrant for men with hormone receptor-positive (HR+),
human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic
breast cancer
Atezolizumab combined with nab-paclitaxel - ANSWER -in breast CA is based on the
PD-L1 expression on tumor-infiltrating immune cells
Olaparib - ANSWER -Breast cancer
-metastatic,
-HER2-negative -germline BRCA-mutated (gBRCAm)
Tvec indication - ANSWER -second-line setting
- patients with skin involvement
-not metastatic
platinum-sensitive disease - ANSWER =/> 6 months
<6 months - ANSWER platinum refractory
